Nephrology Dialysis Transplantation, cilt.7, sa.5, ss.422-426, 1992 (SCI-Expanded)
Patients receiving chronic haemodialysis treatment are known to have a high prevalence of anti-panel antibodies (anti-lymphocyte, antimonocyte, and anti-endothelial cell) originating from a number of different possible sensitizing events such as blood transfusions, multiparity, or renal transplantation. © 1992 European Dialysis and Transplant Association-European Renal Association.